Skip to main content

Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”

Clinical Pharmacokinetics volume 58, pages 959–960 (2019)Cite this article

A Letter to the Editor to this article was published on 03 June 2019

The Original Article was published on 04 April 2019

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 49.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  1. Concordet D, Gandia P, Montastruc J-L, Bousquet-Mélou A, Lees P, Ferran A, et al. Levothyrox® new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. Epub 2019 Apr 4. https://doi.org/10.1007/s40262-019-00747-3.

  2. Gottwald-Hostalek U, Uhl W, Wolna P, Kahaly GJ. New levothyroxine formulation meeting 95-105% specification over the whole shelf-life: results from two pharmacokinetic trials. Curr Med Res Opin. 2017;33:169–74.

    Article  CAS  Google Scholar 

  3. Guidance for Industry. Draft guidance on levothyroxine sodium. https://www.accessdata.fda.gov/drugsatfda_docs/psg/Levothyroxine_draft_Oral tab_RLD 021116 021210 021301 021342 321402_RC12-14.pdf. Accessed 24 May 2019.

  4. Jiang W, Makhlouf F, Schuirmann DJ, Zhang X, Zheng N, Conner D, et al. A bioequivalence approach for generic narrow therapeutic index drugs: evaluation of the reference-scaled approach and variability comparison criterion. AAPS J. 2015;17(4):891–901.

    Article  CAS  Google Scholar 

  5. Peeters RP, Visser TJ. Metabolism of thyroid hormone [Updated 2017 Jan 1]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext. South Dartmouth: MDText.com, Inc.; 2000. https://www.ncbi.nlm.nih.gov/books/NBK285545/. Accessed 24 May 2019.

Download references

Author information

Authors and Affiliations

  1. Service de Biochimie, Unité de Pharmacologie Bioclinique, Centre Hospitalier Universitaire Avicenne (APHP), 125 Route de Stalingrad, 93009, Bobigny Cedex, France

    Patrick Nicolas

Authors
  1. Patrick Nicolas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Nicolas.

Ethics declarations

Funding

No external funding was used in the preparation of this letter.

Conflict of interest

Patrick Nicolas declares no potential conflicts of interest relating to this letter.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nicolas, P. Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”. Clin Pharmacokinet 58, 959–960 (2019). https://doi.org/10.1007/s40262-019-00778-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-019-00778-w